Reactivation of hepatitis B virus (HBV) has recently been reported as a fatal complication in patients undergoing cytotoxic chemotherapy. We herein describe a case of reactivation in a 76-year-old man who had undergone pelvic exenteration for colorectal cancer (CRC). He was treated with a modified FOLFOX6 chemotherapy regimen after the operation. Thirteen months later, his laboratory data showed severe liver dysfunction. His hepatitis B surface antigen (HBsAg) test was positive, and his HBV-DNA level was elevated. We diagnosed the patient with HBV reactivation as his HBsAg test was negative before starting chemotherapy. His liver dysfunction improved after administration of entecavir. This is the first report describing HBV reactivation following chemotherapy for an HBsAg-negative CRC patient.
Introduction
Hepatitis B virus (HBV) reactivation has been reported to be a fatal complication in patients undergoing cytotoxic chemotherapy. It has generally been considered that only hepatitis B surface antigen (HBsAg)-positive carriers are at risk for HBV reactivation following systemic chemotherapy or immunosuppressive therapy. However, HBV reactivation has recently been reported among HBsAg-negative patients with previous HBV infection. Even though it appeared that HBV had been completely eliminated from these patients, viral genomes were later detected in the liver tissue (1, 2) . The risk of HBV reactivation has been associated with the use of rituximab, high-dose steroid therapy, hematopoietic stem cell transplantation, and solid organ transplantation. HBV reactivation is well documented in patients with hematological malignancies, especially in those with malignant lymphoma (3, 4) . In contrast, there have been few cases of HBV reactivation reported among patients with solid cancers (5).
Globally, colorectal cancer (CRC) is the fourth most common cancer-related cause of death (6), and its incidence has been increasing in Japan. Roughly 30% of patients with resectable CRC are candidates for adjuvant chemotherapy (7) . Current guidelines recommend adjuvant chemotherapy for stage III patients because pivotal clinical trials revealed that an oxaliplatin-based regimen of adjuvant chemotherapy for stage III CRC confers a significant survival advantage (8, 9) . Accordingly, many CRC patients have been treated with chemotherapy, but HBV reactivation in HBV-negative CRC patients following chemotherapy has not been described. Ling and colleagues reported that the risk of HBV reactivation is extremely low among CRC patients treated with oxaliplatin-based chemotherapy (10) . The present report is the first known case of HBV reactivation in an HBsAgnegative individual who had undergone cytotoxic chemotherapy for CRC.
Case Report
A 76-year-old man underwent pelvic exenteration for CRC with direct bladder invasion. A final diagnosis of stage III CRC was reached based on his pathological examination results. According to current guidelines, treatment with the mFOLFOX6 regimen was initiated. Before the start of chemotherapy, the patient was negative for HBsAg and HBV-DNA was undetectable; however, his tests for hepatitis B surface antibody (anti-HBs) and the antibody to hepatitis B core antigen (anti-HBc) were positive. After nine courses of this treatment, a liver metastasis was detected on a computed tomography (CT) scan. We treated the liver metastasis with percutaneous radiofrequency ablation (RFA) therapy. Following RFA, the regimen was changed to mFOLFOX6 plus bevacizumab. After 10 courses, his peripheral neuropathy was rated as grade 3 (CTCAE v4.0) due to oxaliplatin toxicity. Accordingly, we changed the regimen again, this time to sLV5FU2 plus bevacizumab.
Three weeks after the last course of chemotherapy, the patient was referred to our hospital with a complaint of general fatigue. Laboratory data showed an increase in serum transaminase levels [aspartate aminotransferase (AST) 4,430 IU/L, alanine aminotransferase (ALT) 2,233 IU/L], and total bilirubin (4.3 mg/dL) and decreased prothrombin (PT) activity (66%) ( Table) . A CT scan revealed liver cysts and a hypodense area corresponding to the location where RFA had been performed previously. No tumors or dilation of biliary ducts were detected. The patient was positive for serum HBsAg chemiluminescence immunoassay (CLIA) method , anti-HBc, IgM-anti-HBc (index 1.4, CLIA method) and hepatitis B e antibody (anti-HBe), and he had elevated levels of HBV-DNA 5.0 log copies/mL, real-time polymerase chain reaction (PCR) method and hepatitis B core-related antigen (HBcrAg) (4.6 log U/mL, chemiluminescence enzyme immunoassay (CLEIA) method . Other markers of hepatitis viral infection (e.g., hepatitis A, C, and E viruses; Epstein-Barr virus, and cytomegalovirus) were all negative. Anti-nuclear and anti-mitochondrial antibodies were also negative. During treatment, the patient had not undergone any procedures associated with high risk for HBV infection, such as transfusion. In addition, his IgM-anti-HBc level was modestly elevated. Therefore, the possibility of HBV infection at chemotherapy initiation was very low. A liver biopsy revealed severe hepatic cell denaturation, many areas of focal necrosis, and minimal fibrosis, which was consistent with acute hepatitis. A diagnosis of HBV reactivation due to chemotherapy was ultimately reached. We tried twice to identify the HBV genotype by enzyme immunoassay (EIA), but this could not be determined. Since the time of his admission to our hospital, the patient was treated with glycyrrhizinic acid by intravenous injection (100 mL/day). After the patient was diagnosed with HBV reactivation, we administered a daily dose of 0.5 mg entecavir (ETV). Two weeks later, his transaminase levels, total bilirubin, and PT had recovered to normal ranges. After two more weeks, the patient's HBV DNA and HBcrAg levels were undetectable, and he became negative for HBsAg (Figure) . He recovered from hepatitis due to HBV reactivation, but his performance status (PS) remained poor, and it was impossible to continue cytotoxic chemotherapy for CRC. Therefore, he received palliative care, and ETV was continued as a prophylactic treatment against HBV reactivation. 
Discussion
While HBV reactivation is a known complication in patients with solid cancers who are treated with chemotherapy, the risk factors and incidence rates for HBV reactivation are largely unknown. In CRC patients undergoing chemotherapy, the risk of HBV reactivation has been reported to be extremely low (10) . In fact, there has been only one report of HBV reactivation during chemotherapy in a HBsAgpositive CRC patient (11) , and no reports in HBs-negative patients. Accordingly, routine HBV screening may be unnecessary for CRC patients undergoing treatment with oxaliplatin-or irinotecan-based chemotherapy. Taking into consideration the follow-up costs, routine testing for HBV reactivation among CRC patients might not be cost effective because of the low risk of reactivation. However, we have previously described HBV reactivation during CRC chemotherapy in an HBsAg-negative patient. Although Japanese guidelines recommend routine HBV DNA screening of HBsAg-negative and anti-HBc-or anti-HBs-positive patients during and after chemotherapy (12), we did not perform such testing prior to HBV reactivation. It should be recognized that HBV-DNA should be routinely monitored, and we must therefore strictly follow this guideline.
A recent randomized controlled study revealed that ETV prophylaxis against HBV reactivation can effectively prevent rituximab-induced HBV reactivation in patients with lymphoma and resolved HBV infection (13) . The study demonstrated that the cumulative HBV reactivation rate at 18 months after rituximab-based chemotherapy was 25.9% in the non-ETV prophylaxis group. The HBV reactivation rate was markedly higher than that of CRC patients treated with chemotherapy, and this high incidence of HBV reactivation was attributable to rituximab. Rituximab is considered to be a major risk factor for HBV reactivation in HBsAg-negative patients with lymphoma. Steroid administration may also be associated with HBV reactivation. Our patient used a dose of 6.6 mg dexamethasone once per course for anti-emesis. The total amount of dexamethasone was 132 mg, therefore it is unlikely that the steroids induced the HBV reactivation. In patients with solid cancer and resolved hepatitis B, prophylaxis of HBV reactivation before chemotherapy is not currently recommended in most treatment guidelines (14, 15) . While the mechanism by which HBV reactivation occurs remains uncertain, transaminase and HBV-DNA should be monitored in patients with resolved hepatitis B; this should be done in both patients with hematologic malignancies and solid cancers, even though the likelihood of HBV reactivation during chemotherapy for CRC is low.
In the present case, we tried twice to identify the HBV genotype by EIA, but the results were inconclusive. The genotype may not be determined if the quantity of HBsAg is low or if the patient has a genotype other than A, B, C, or D or a mutation of the PreS2 domain (16) . We assume that the results were unclear in the present case due to the patient's low levels of HBsAg. Therefore, we should have attempted to use either the PCR-invader or direct sequencing method.
In terms of HBV viral kinetics, the patient's serum HBV DNA level became undetectable within four weeks of ETV administration. Dong and colleagues reported that the decline of HBV DNA 30 days after ETV administration is around 5.0 log copies (17) . The viral kinetic analysis presented herein is consistent with that report.
Although our patient survived, HBV reactivation should be recognized as a life-threatening complication. Further prospective studies will be necessary to elucidate the risk of HBV reactivation in CRC patients undergoing chemotherapy.
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